Login
Navigate Fool.com
Will BIIB beat
the market?

Biogen Idec

NASDAQ: BIIB

Community Rating: 4 Stars: Favorite

306.20 8.22 (2.76%)

REAL-TIME: Last trade at

Extended Hours: $311.08 $4.88 (1.59%)
Quote as of (NASDAQ)


company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $300.50
Previous Close $297.98
Daily Range $300.00 - $309.17
52-Week Range $194.66 - $358.89
Market Cap $72.4B
P/E Ratio 38.15
Dividend (Yield) $0.00 (0.0%)
Volume 1,777,115
Average Daily Volume 2,010,252
Current FY EPS $11.29

How do you think BIIB
will perform against the market?

Top BIIB Bull/Bear Pitches

 

StockDocStan (1.9)
Submitted September 7, 2011

The clear leader in the independent biotechs is NOT likely to stay independent for long. I expect a buyout by Roche or even Pfizer or Merck in the next 6 months.

0 Replies Reply Report this Post
 

NetscribeBiotech (< 20)
Submitted February 19, 2007

Biogen Idec Inc, born in 2003 post the merger of Biogen and Idec Pharmaceuticals, develops, manufactures and commercializes novel therapies. With five approved products viz. Avonex, Rituxan, Tysabr, A … More

4 Replies Reply Report this Post

News & Commentary Rss Feed

Biotech Earnings Preview

A rundown of what to expect from Gilead Sciences, Arena Pharmaceuticals, and Biogen Idec.

Johnson & Johnson: Why Top Funds Are Buying

Pre-Market Earnings Report for April 23, 2014 : PG, BA, BIIB, DOW, EMC, TMO, ERIC, PX, GD, NSC, JCI

Pre-Market Earnings Report for April 23, 2014 : PG, BA, BIIB, DOW, EMC, TMO, ERIC, PX, GD, NSC, JCI, RAI

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

What to Watch for in Biotech Earnings This Week

Several top biotechs will report earnings this week. Will they reignite the biotech rally or drive share prices even lower?

Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape

With four multiple sclerosis therapies already approved, another under FDA review, and one more in mid-stage studies, this biopharmaceutical company is addressing this disease head on.

This Medical Marijuana Stock Is Not What You Think

GW Pharmaceuticals is more like Biogen, Teva Pharmaceuticals, and Acorda Therapeutics than penny-stock companies hocking medical marijuana.

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Here's what you need to know about Amgen (AMGN) and Biogen's (BIIB) upcoming first quarter earnings report.

3 Biotech Opportunities Following This Selloff

Here's a second chance to invest in companies with viable growth potential.

Health Care Stocks: Check Out This Low-Cost Market Beater

These health care stocks have been growing by double digits. Should you buy?

See More BIIB News...

Sector

Healthcare

Industry

Drugs

Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website: http://www.biogenidec.com/

More details for Biogen Idec Jobs
Biogen Idec reviews from employees

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks